Chronic lymphocytic leukemia: new prognostic markers.
| Extensively studied |
| Serum markers |
| - Thymidine-kinase, sCD23, Beta-2 microglobulin |
| FISH cytogenetics |
| IgVH mutational status |
| V3.21 expression |
| CD38 expression |
| ZAP-70 expression |
| Requiring further studies |
| Serum markers |
| - VEGF, CD20, CD49d, Thrombopoietin |
| Telomere length |
| Telomerase activity |
| MCL-1 expression |
| Activation induced cytidine deaminase (AID) mRNA |
| Lipoprotein lipase A expression |
| ADAM29 expression |
| HS1 protein expression |
| Micro RNA genetic signature |
| CLLU1 expression |
| Treatment-related |
| Response to therapy |
| - achievement of minimal residual disease–negative |
| status |
| Extensively studied |
| Serum markers |
| - Thymidine-kinase, sCD23, Beta-2 microglobulin |
| FISH cytogenetics |
| IgVH mutational status |
| V3.21 expression |
| CD38 expression |
| ZAP-70 expression |
| Requiring further studies |
| Serum markers |
| - VEGF, CD20, CD49d, Thrombopoietin |
| Telomere length |
| Telomerase activity |
| MCL-1 expression |
| Activation induced cytidine deaminase (AID) mRNA |
| Lipoprotein lipase A expression |
| ADAM29 expression |
| HS1 protein expression |
| Micro RNA genetic signature |
| CLLU1 expression |
| Treatment-related |
| Response to therapy |
| - achievement of minimal residual disease–negative |
| status |